Quotient Sciences Integrates Drug Substance into Translational Pharmaceutics Platform
The full integration of drug substance R&D and manufacturing follows a year after the company’s acquisition of its Alnwick, UK site and provides customers in the pharmaceutical and biotech industry a more streamlined approach from candidate selection through to commercialization. The integrated platform of Quotient Sciences enables innovators to adjust formulations and dosing in real time.
“Our Translational Pharmaceutics platform is now in its 15th year and has accelerated development timelines for more than 500 drug programs. We remain the only outsourcing partner able to offer innovators the ability to manufacture, release, and dose under one organization. This approach is proven to shave 12-months off timelines and, by adding drug substance synthesis, the timeline from candidate selection to clinic can be further accelerated by 2-4 months,” said Mark Egerton, CEO of Quotient Sciences.
“By fully integrating drug substance with drug product and clinical testing activities, Quotient Sciences can closely align manufacturing and dosing workflows, greatly improving R&D efficiencies, and increasing the potential for clinical and commercial success,” stated Peter Scholes, CSO of Quotient Sciences. “In fact, an independent study by the Tufts Center of the Study of Drug Development (CSDD) showed Translational Pharmaceutics delivered $200milllion in drug development cost saving per approved drug.”